OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy	144
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications	43
An overview of the time trade-off method: concept, foundation, and the evaluation of distorting factors in putting a value on health	40
Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic	34
Organizational measures aiming to combat COVID-19 in the Russian Federation: the first experience	32
Distinguishing features in the assessment of mHealth apps	30
Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses	27
Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review	27
Tools to assess the quality of life in patients with Parkinson’s disease: a systematic review	26
First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China	24
Health-related quality of life in patients with chronic kidney disease	20
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments	20
Evaluation instruments for executive functions in children and adolescents: a systematic review	17
The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries	14
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China	14
Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia	14
Valuing health outcomes: developing better defaults based on health opportunity costs	14
Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease	13
Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing	13
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease	13
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review	12
A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population	12
Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study	12
Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region	12
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore	11

Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis	11
Economic evaluation of a multimodal intervention in pre-frail and frail older people with diabetes mellitus: the MID-FRAIL project	11
Burden of communicable diseases and cost of illness: Asia pacific region	11
The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review	10
‘Without data, you’re just another person with an opinion’	10
Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia	10
The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature	10
Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder	9
How do biosimilars sustain value, affordability, and access to oncology care?	9
The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis	9
Can we achieve affordable cancer medicine prices? Developing a pathway for change	9
Artificial intelligence in outcomes research: a systematic scoping review	8
Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review	8
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	8
Elderly individuals with diabetes and foot ulcer have a probability for healing despite extensive comorbidity and dependency	8
Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system	7
Estimating the economic consequences of substance use and substance use disorders	7
Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures	7
Cost of illness in multiple sclerosis by disease characteristics – A review of reviews	7
Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications	7
Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years	7
Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic	7
A review of quality-of-life in elderly osteoarthritis	7
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia	7
Cannabis use among Canadian adults with cancer (2007–2016): results from a national survey	7
Economic burden associated with stroke in India: insights from national sample survey 2017-18	7
Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience	7
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	7
Barriers and facilitators of exploiting the potential of value-added medicines	6
Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period: productivity losses due to premature mortality	6
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review	6
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer	6
Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma	6
Not cost-effective at zero price: valuing and paying for combination therapies in cancer	6
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Gr	6
The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology	6
Disease burden on health care by pain severity and usual analgesic treatment in patients with symptomatic osteoarthritis: a Spanish nationwide health survey	6
Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia	6
An update on the economic burden of type 2 diabetes mellitus in China	6
The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways	6
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	6
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis	6
Exploring the consistency of the SF-6Dv2 in a breast cancer population	6
Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study	6
Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan	6
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer	6
Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain	6
Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews	5
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspe	5
Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients	5

Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China	5
Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence	5
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention	5
Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis	5
Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia	5
The costs of treatment resistant depression: evidence from a survey among Italian patients	5
Pharmacoeconomics of obesity in China: a scoping review	5
Cardiovascular outcome trials of glucose-lowering therapies	5
Short-term societal economic burden of first-incident type 2 diabetes-related complications – a nationwide cohort study	5
A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population	5
Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment	5
Direct medical costs of breast cancer in Jordan: cost drivers and predictors	5
Letter to the editor on ‘cognitive behavior therapy for health anxiety: systematic review and meta-analysis of clinical efficacy and health economic outcomes’	4
Early technology assessment of using whole genome sequencing in personalized oncology	4
The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol	4
A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.	4
Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States	4
Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia	4
Assessment of women’s treatment preferences for vasomotor symptoms due to menopause	4
Impact of surgical instrumentation on hospital length of stay and cost of total knee arthroplasty	4
Assessing the pricing and benefits of oncology products: an update	4
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	4
Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study	4
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	4
Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients	4
Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience	4
Burden of illness the first year after diagnosed bladder dysfunction among people with spinal cord injury or multiple sclerosis – a Danish register study	4
Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain	4
A pre-vaccine analysis using the Health Belief Model to explain parents’ willingness to vaccinate (WTV) their children in the United States: implications for vaccination programs	4
Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies	4
In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy	4
Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment	4
Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting	4
Cost-related nonadherence for prescription medications: a cross-sectional study in Jordan	4
How can societal culture and values influence health and rehabilitation outcomes?	4
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2– metastatic breast cancer in the United States	3
Burden of depression among Canadian adults with cancer; results from a national survey	3
Evaluation of quality of pharmacoeconomic studies involved in traditional Chinese medicine in China	3
Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer	3
The value of communicating with patients in their first language	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
A systematic review of cost-effectiveness analyses across the acute kidney injury landscape	3
All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain	3
Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck	3
Pharmacist-directed care to optimize medication use: a healthcare imperative in the United States	3
A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury	3
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	3
Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review	3
Barriers to implementing pharmacoeconomics: interview study	3
Contemporary outcomes studies to identify and mitigate the risk in patients with premature cardiovascular disease	3
Bringing the patient’s perspectives forward in drug development and health-care evaluation	3
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events	3
Budget impact analysis of medicines: estimated values versus real-world evidence and the implications	3
Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review	3
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis	3
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china	3
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis	3
A landscape analysis and discussion of value of gene therapies for sickle cell disease	3
Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States	3
A review of caregiver costs included in cost-of-illness studies	3
Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model	3
Incorporating health inequality impact into economic evaluation in low- and middle-income countries: a systematic review	3
Characterization of health-related quality of life based on the EQ-5D-5L questionnaire in head-and-neck cancer patients undergoing modern radiotherapy	3
Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic Jordanians: a Markov modeling of cardiovascular diseases prevention	3
Summary of the 2020 AHRQ research meeting on ‘advancing methods of implementing and evaluating patient experience improvement using consumer assessment of healthcare providers and systems (CAHPS®) sur	3
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	3
Patient associations and clinical oncology research: how much does a patient’s voice really matter?	3
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	3
Burden of disease and costs of infections associated with cardiac implantable electronic devices	3
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	3
The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices	3